Showing posts with label clinical trials. Show all posts
Showing posts with label clinical trials. Show all posts

Sunday, March 6, 2011

Mesothelioma Clinical Trials

One of the thwarting facts near malignant mesothelioma is the opposition of the someone cells generated by the disease to chemotherapy and therapy handling. Physicians are constantly investigating new medications as wellspring as alone new concepts for speed or halting the sex of cancerous cells, as intimately as methods of destroying them. New uses of ingrained engineering proceed into attempt, much as the exercise of the magnitude modulated radiation technique for therapy. Factor therapy and immunotherapy both initiate to utilize the body's born methods of warring invasive disease for the intention of targeting somebody cells.

Much of the investigating for new communicating modalities centers on chemotherapy: both new drugs and new methods of delivering the drug effectively to the diseased paper. All new medications to be oversubscribed in the Joint States moldiness go finished a clinical attempt deliver antecedent to beingness approved by the Food and Drug Administration (FDA). In galore cases, anti-cancer drugs utilised for mesothelioma discourse are medications that score been expressly authorized for a taxon of soul discourse, but not for use with mesothelioma. Using an authorised human treatment for a non-approved mansion handling is not unaccustomed, nor contraband low FDA guidelines.

Clinical trials are also conducted simply to see if there are surmount discourse options to be institute using tools that are already getable for battle someone. That's why numerous clinical trials for mesothelioma are experiments to see if the use of existing constellation drugs in one combination or added instrument be effectual in combating asbestos house. Substance from FDA commendation, a decent conducted clinical run instrument launch the transparent valuate of one organise of communication or added because it meets the professional medical standards for much tests

Saturday, October 2, 2010

Trials to target CSCs

U-M stem cell trial shows promise against breast cancer by Kim Kozlowski, The Detroit News, September 30, 2010. Excerpt:
The research will be highlighted next week in Detroit during the World Stem Cell Summit, a gathering of 1,200 prominent stem cell scientists, industry leaders and advocates from 30 countries.

Saturday, July 24, 2010

Magic mushrooms & no magic bullet for patient communication


Johns Hopkins tells us that researchers are looking at illegal drugs to help people with OCD (obsessive-compulsive disorder), PTSD (post-traumatic stress disorder), anxiety and depression--anxiety being Cancer Bitch's major bugbear. MDMA aka Ecstacy, says Johns Hopkins health reports, also increases brain levels of oxytocin, which arouses feelings of trust and confidence that can be particularly helpful during psychotherapy. The idea is that a dose of the drug, taken before a talk therapy session, may help individuals with PTSD reduce their fear and anxiety long enough to discuss and process the events that traumatized them. Ketamine aka Special K, is an FDA-approved general anesthetic that is being studied as a fast-acting antidepressant. Ketamine binds to receptors in the brain and blocks the neurotransmitter glutamate that normally activates neurons, thus producing a calming effect.

I haven't tried any of the above, though in high school, the guys in Future Farmers of America were allegedly growing the mushrooms on their school farm. It was the '70s, after all.

You can participate in clinical trials of these drugs (or a placebo)if you meet the criteria. For example, New York University is administering one dose of psilocybin to anxious people with life threatening, advanced, or recurrent cancer. If you're in Baltimore, check a study out here.

University of Rochester is studying whether topical amitriptyline and ketamine cream are effective in treating neuropathy caused by chemo.

There are tons of clinical trials and they can save or at least improve lives, even your own. For example, in researchers in Downstate Illinois are studying how best to get breast cancer survivors to exercise. There's another one on whether flaxseed is helpful in combatting hot flashes. My favorite is one at Fancy Hospital on communication with patients. A major goal: •Determine patients' health communication needs during the first 6 months of care by interviewing patients with breast cancer (as well as their families, caregivers, and healthcare teams) and observing interactions between patients and oncologists throughout the trajectory of care from initial diagnosis through the initial treatment course.

This involves video and extensive interviews. What should also be done:

* HIRE ENOUGH ONCOLOGISTS & STAFF SO THAT THE WAIT TIME IS NOT TWO HOURS FOR CHEMO OR ONCOLOGY APPOINTMENTS.

* REQUIRE DOCTORS TO READ PATIENTS' CHARTS BEFORE ENTERING THE EXAMINATION ROOM.

* REQUIRE DOCTORS TO SIT DOWN DURING PATIENT APPOINTMENTS.

* TRAIN DOCTORS (STARTING WITH MEDICAL STUDENTS) WITH EXTENSIVE ROLE-PLAYING EXERCISES.

* INVITE JEROME GROOPMAN TO TALK TO ALL STAFF ABOUT COMMUNICATION WITH PATIENTS AND FOLLOW WITH SMALL MIXED (SEE POINT BELOW ABOUT MIXING STAFF) DISCUSSION GROUPS ON RELATING AND COMMUNICATING WITH PATIENTS.

* CONTINUE ATTEMPTS TO LOCATE/ENCOURAGE HUMANITY IN DOCTORS AND TO BREAK DOWN THE HOSPITAL HIERARCHY (BASED ON RANK, EDUCATION, CLASS AND MOST OF ALL RACE) BY HOLDING WRITING WORKSHOPS, BOOK AND OTHER DISCUSSION GROUPS, IMPROV & EXERCISE CLASSES AND OTHER ACTIVITIES THAT INCLUDE EVERYONE, FROM IMPORTANT & SELF-IMPORTANT DOCTORS TO CLERICAL STAFF.


* HIRE HOSPITAL CLOWNS TO EASE TENSION & BRAINSTORM WITH THEM ABOUT IDEAS TO EASE ANXIETY AND COMMUNICATION. IT'S HARD TO LISTEN WELL WHEN YOU'RE TENSE.



To search for clinical trials, go here.

Saturday, October 17, 2009

Targeting cancer stem cells

Griffin Securities Announces Investment Opinion on Targeting Cancer Stem Cells, Yahoo Finance, October 9, 2008. First paragraph:
Griffin Securities (“Griffin”), a research-driven investment banking firm, has released an industry report on the subject of targeting cancer stem cells (CSCs). The stem cell hypothesis offers a rational approach to preventing, diagnosing, and treating malignant growth. Covered in the report are five classes of drugs nearing the Phase II clinical trial that provides human proof-of concept data, a crucial stage of development: Notch signaling, PI3k/akt pathway, immunotherapeutics, molecular chaperons, and hedgehog signaling.
See also: Firms Seek to Prove Cancer Stem Cell Hypothesis by Keith A Markey (scientific director at Griffin Securities), Genetic Engineering & Biotechnology News, Oct 15, 2009 (Vol 29, No 18).

Comments: Information can be found online about some of the drugs mentioned in the article by Keith A Markey. Two examples:
  1. Notch signaling: OMP-21M18
    A humanized monoclonal antibody directed against the N-terminal epitope of Notch ligand DLL4 (delta-like 4) with potential antineoplastic activity. Anti-DLL4 monoclonal antibody OMP-21M18 binds to the membrane-binding portion of DLL4 and prevents its interaction with Notch-1 and Notch-4 receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may impede tumor angiogenesis. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated into the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium.
    One Phase 1 trial of OMP-21M18 [ClinicalTrials.gov Identifier: NCT00744562].

  2. Hedgehog signaling: IPI-926
    An orally bioavailable, cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Specifically, Hedgehog pathway inhibitor IPI-926 binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations. The Hh signaling pathway plays an important role in proliferation of neuronal precursor cells in the developing cerebellum and other tissues.
    One Phase 1 trial of IPI-926 [ClinicalTrials.gov Identifier: NCT00761696].
A search of the Canadian Cancer Trials database indicated no trial sites, for either of these two particular trials, that are located in Canada.

Friday, July 24, 2009

Translation of knowledge about CSC into clinical use

Radiation Therapy Oncology Group Translational Research Program Stem Cell Symposium: Incorporating Stem Cell Hypotheses into Clinical Trials. Authors: Wendy A Woodward, Robert G Bristow, Michael F Clarke, Robert P Coppes, Massimo Cristofanilli, Dan G Duda, John R Fike, Dolores Hambardzumyan, Richard P Hill, Craig T Jordan, Luka Milas, Frank Pajonk, Walter J Curran, Adam P Dicker, Yuhchyau Chen. Int J Radiat Oncol Biol Phys 2009(Aug 1); 74(5): 1580-91 [Epub 2009(Jun 17)]. PubMed Abstract:
At a meeting of the Translation Research Program of the Radiation Therapy Oncology Group held in early 2008, attendees focused on updating the current state of knowledge in cancer stem cell research and discussing ways in which this knowledge can be translated into clinical use across all disease sites. This report summarizes the major topics discussed and the future directions that research should take. Major conclusions of the symposium were that the flow cytometry of multiple markers in fresh tissue would remain the standard technique of evaluating cancer-initiating cells and that surrogates need to be developed for both experimental and clinical use.

Friday, November 7, 2008

OncoMed press release

OncoMed Pharmaceuticals press release, November 4, 2008 [PDF]. Excerpt:
OncoMed's lead anti-cancer stem cell antibody, OMP-21M18, entered human clinical studies earlier this year with the initiation of a Phase I trial in patients with advanced solid tumors. OMP-21M18 targets a major cancer stem cell pathway, and is a part of OncoMed's collaboration with GlaxoSmithKline. The Phase I clinical trial is designed to evaluate the safety of escalating doses of OMP-21M18 in patients with solid tumors who have received previous treatment. Pharmacokinetics and initial indications of efficacy will also be assessed. OMP-21M18 is the first anti-cancer stem cell antibody against this novel target critical to cancer stem cells growth and development.
For news items about this press release, see, for example: "OncoMed Pharmaceuticals Completes Series B Financing: Lead Cancer Stem Cell Product Candidate Enters Clinical Trials", November 4, 2008 in Yahoo! Finance and The Earth Times. See also: OncoMed raises $93M in add-on funding, Lisa Sibley, Silicon Valley/San Jose Business Journal, November 4, 2008.